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One sentence summary:  Thanatin targets protein-protein interactions between LptA and 
LptD in the periplasmic bridge required for LPS transport. 
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Abstract 
With the increasing resistance of many Gram-negative bacteria to existing classes of 
antibiotics, identifying new paradigms in antimicrobial discovery is an important research 
priority. Of special interest here are the proteins required for the biogenesis of the 
asymmetric Gram-negative bacterial outer membrane. Seven Lpt proteins (LptA-G) 
associate in most Gram-negative bacteria to form a macromolecular complex spanning the 
entire envelope, which transports LPS molecules from their site of assembly at the inner 
membrane to the cell surface, powered by ATP hydrolysis in the cytoplasm. The periplasmic 
protein LptA comprises the protein bridge across the periplasm, which connects LptB2FGC 
at the inner membrane to LptD/E anchored in the outer membrane. We show here that the 
naturally occurring insect-derived antimicrobial peptide thanatin targets LptA and LptD in the 
network of periplasmic protein-protein interactions required to assemble the Lpt complex, 
leading to inhibition of LPS transport and OM biogenesis in Escherichia coli. 
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Main text 
The asymmetric outer membrane (OM) plays a critical role in protecting Gram-negative 
bacteria from extracellular cytotoxic molecules, including antibiotics. This unique bilayer 
comprises lipopolysaccharide (LPS) molecules in the outer leaflet and membrane 
glycerophospholipids in the inner leaflet.  Integral OM proteins (OMPs) are crucial for the 
biogenesis of the OM, as well as for controlling the uptake and export of essential nutrients 
and signalling molecules across the OM. Of special interest here are the seven proteins 
(LptA-G) needed to transport LPS molecules from their site of assembly at the inner 
membrane (IM), across the aqueous periplasm, to their final cell surface location, during OM 
biogenesis (1-3). The LptA-G proteins associate to form a macromolecular complex, which 
spans the entire envelope (4, 5). The periplasmic protein LptA, likely as a head-to-tail 
oligomer, forms a protein bridge spanning the periplasm. LPS molecules are pushed across 
this bridge (6-10), from LptB2FGC anchored in the inner membrane, to the LptDE complex 
embedded in the OM (Figure 1A) (11, 12 , 13-16), powered by ATP hydrolysis in the 
cytoplasm (4). We report here that the naturally occurring, insect-derived host-defense 
peptide thanatin (Figure 1B) targets both LptA and LptD in Escherichia coli. 
 Thanatin was first isolated from the hemipteran insect Podisus maculiventris (spined 
soldier bug) in 1996 (17). The peptide contains 21 amino acids 
(GSKKPVPIIYCNRRTGKCQRM) with a disulfide bond between Cys11 and Cys18. 
Antimicrobial activity for thanatin was reported against E. coli, Salmonella typhimurium, 
Klebsiella pneumoniae, and Enterobacter cloacae with MICs <1.5 µM, with weaker activity 
against Erwinia carotovora and Pseudomonas aeruginosa (MICs 10-12 µM). Whereas no 
activity was seen against Staphylococcus aureus, thanatin is active against several other 
Gram-positive bacteria with MICs ≈1-5 µM. Of special interest is the observation that the 
enantiomeric form (D-thanatin) loses much of its activity against all the Gram-negative 
strains tested, indicating a likely chiral target. 
 The mechanism of action of thanatin is so far unknown. The peptide is bactericidal 
against E. coli, shows only weak permeabilizing effects on the inner or outer membrane, and 
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does not cause hemolysis of blood erythrocytes even at 100x the minimal inhibitory 
concentration (MIC) (17-20). We confirmed that thanatin has no membrane-permeabilizing 
effects on E. coli. The fluorescent dye Sytox-Green does not penetrate E. coli cells treated 
with thanatin even at 100 µg/mL (see section-3, Supplementary Information (SI)). Moreover, 
no release into the external medium of ß-lactamase expressed in the periplasm, or of ß-
galactosidase expressed in the cytoplasm of E. coli could be detected upon exposure to 
thanatin (see SI). Thus, even at concentrations much higher than the minimal inhibitory 
concentration (MIC), neither the IM nor the OM of E. coli are permeabilized by treatment with 
thanatin, unlike what is seen with some other cationic antimicrobial peptides, such as 
polymyxin B, colistin or protegrin I (21, 22). 
 The effects of thanatin on macromolecule biosynthesis were examined by monitoring 
the incorporation of appropriate [3H]-labeled precursors into macromolecules in E. coli 
ATCC25922 (see Section-4, SI). No inhibition of protein, RNA, DNA or cell wall biosynthesis 
was observed. To analyze effects on morphology, E. coli cells were grown with thanatin at 
concentrations causing significant growth inhibition and then examined in thin sections by 
transmission electron microscopy (TEM). This revealed frequent defects in membrane 
architecture, with accumulations of membrane-like material inside cells (Figure 2A/B). Such 
multilayered membrane folds inside the cell are typical of those reported for E. coli in which 
LPS transport is inhibited by down-regulation of LptA/B, LptC or LptD (5, 16). The effects of 
thanatin on E. coli were also monitored by laser scanning stimulated emission depletion 
(STED) fluorescence microscopy, with staining of membranes by the membrane dye FM4-
64, of nucleoids by DAPI, and using Sytox-Green to detect permeabilized cells (Figure 
2C/D). These studies revealed frequent accumulations of membrane-like material in the form 
of knobs stained bright red by FM4-64, as well as elongated cell assemblies, with neither 
effect visible in the absence of thanatin. Nucleoids stained with DAPI were not influenced 
significantly by thanatin, and again no significant staining was observed by Sytox-Green. 
These results reveal that thanatin causes defects in membrane assembly in E. coli. 
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 A fluorescent derivative (thanatin-BDP-FL; MIC ≈ 1-2 µg/mL, Figure 1B) was used for 
STED fluorescence imaging. This probe stained the E. coli envelope, with marked focal 
accumulations (as green fluorescent knobs) across the cell and at the cell poles (Figure 2E). 
This behavior is reminiscent of fluorescent labeling of OM proteins that accumulate into 
membrane islands or clusters and at the poles in Gram-negative bacteria (23, 24). The 
interaction of thanatin with OM proteins in E. coli was tested directly by photoaffinity labeling 
experiments. Two thanatin-derived photoprobes were synthesized containing photoproline 
(25, 26), in place of either Pro5 or Pro7, together with an N-terminal PEG-linker and biotin 
tag for pull-down assays (Figure 1B; sections-2 and -6, SI). Both probes (thanatin-PAL5, and 
thanatin-PAL7) maintained antimicrobial activity against E. coli ATCCC25922 (MICs 2-4 
µg/mL) and photolabeled the same membrane proteins in vivo, as shown in Western blotting 
for thanatin-PAL5 in Figure 3A. In a competitive photolabeling experiment with native 
thanatin (200 µg/mL) as competitor, thanatin-PAL5 (2 µg/mL) labeling of the ≈95 kDa band 
largely disappeared from the blot whereas the other signals showed reduced labeling 
(Figure 3A). When the in-vivo photolabeled membrane protein extract was analyzed under 
non-reducing conditions to retain disulfide bonds, a shift of the ≈95 kDa band to ≈130 kDa 
was seen in the Western blot (Figure 3B, and SI). This change in gel electrophoretic mobility 
is very characteristic of that reported for E. coli LptD in the disulfide-reduced and disulfide-
oxidized forms (LptDox ≈130 kDa; LptDred ≈ 90 kDa) (27, 28).  
 It was technically not possible to identify photolabeled proteins directly from the 
Western blots. To identify thanatin interaction partners in a hypothesis-free, discovery-driven 
approach, we used the photoaffinity interaction mapping strategy outlined above, in 
combination with mass spectrometry-based proteomic analysis, which allows for the 
multiplexed and label-free quantification of E. coli interaction partners. Thanatin-PAL5 photo-
labeled and untreated control E. coli ATCC25922 cells were lysed and biotinylated proteins 
purified using streptavidin-functionalized agarose resin. Enriched proteins were 
proteolytically digested and subsequently identified using high-performance liquid 
chromatography tandem mass spectrometry (HPLC-MS/MS). Four hundred proteins were 
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identified at a False-Discovery-Rate (FDR) below 1%. Relative quantitative comparison 
revealed the specific and photolabeling-dependent enrichment of three proteins, namely 
LptD, LptA and BamB, of which LptD and LptA were most significant (Figure 3C). Whereas 
photolabeling of the membrane protein LptD was already suggested by the Western blotting 
experiments described above, photolabeling of LptA, a small (≈18 kDa) soluble periplasmic 
component of the LPS transport pathway (Figure 1A), was unexpected. 
 Spontaneous thanatin resistant (ThanR) mutants of E. coli ATCC25922 were sought 
for genetic analysis. ThanR mutants could be isolated at low frequency (≈ 1 in 108 CFUs; 10-6 
%) by passaging on MH-II agar containing 10-50 µg/mL thanatin. Five ThanR mutants were 
selected that remained stable over at least four passages on thanatin-free agar (see section-
7, SI). Three mutants showed no difference in growth behavior compared to the wild type 
(wt) in MH-II media and showed no increased sensitivity on MH-II agar supplemented with 
0.5% SDS and 1mM EDTA. Also, the susceptibility of all mutants to a series of standard 
antibiotics was unchanged (see section-7, SI). Whole genome sequencing of the three 
ThanR mutants revealed several mutations compared to the wt genome, including in lptA as 
the only mutated gene common to all three. Moreover, one resistant mutant (ThanR-8) 
contained only a single point mutation in the entire genome, corresponding to a change of 
glutamine to leucine at position 62 (Q62L) in LptA. We also tested whether the identified 
mutations Q62L-LptA and D31N-LptA would confer resistance to thanatin when introduced 
into a sensitive E. coli strain. For this, genes encoding LptA with a His6 tag at the C-terminus 
(LptA-His6), as well the corresponding mutated variants (Q62L-LptA-His6, and D31N-LptA-
His6), were introduced into E. coli. Introduction of the mutant alleles led to a markedly higher 
MIC for thanatin, whereas introduction of the wt sequence (LptA-His6) gave no significant 
change in MIC (see section-7, SI). In summary, the genetic and photolabeling results reveal 
a link between the antimicrobial activity of thanatin and LptA, and point to LptA as an 
interaction partner for thanatin in E. coli. On the other hand, no mutations in lptD were 
detected in the genomes of the three analysed ThanR mutants. 
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 To date no small molecules (apart from LPS) are known to interact with LptA, so we 
tested whether thanatin can directly bind to LptA in vitro. A recombinant full-length LptA (with 
a His6 tag fused to the C-terminus (LptA-His6) was produced in E. coli BL21(DE3) and 
purified to apparent homogeneity by SDS-PAGE after Ni-NTA affinity and anion exchange 
chromatography (see section-8, SI). The binding of thanatin-BDP-FL (Figure 1B) to LptA-
His6 was then studied by fluorescence polarization (FP), and of thanatin binding to LptA 
labeled with Dylight650 by thermophoresis. Using both biophysical methods, fitting the 
binding isotherm to a 1:1 Langmuir binding model (see section-9, SI) gave by FP a Kd of 
12±3 nM and by thermophoresis of 20±1 nM. In control experiments using the enantiomeric 
form of thanatin (comprising all D-amino acids), no interaction of D-thanatin with LptA was 
observed by FP. The binding of thanatin to LptD was also measured in vitro using a 
recombinant His-tagged LptD/E complex purified from E. coli (see section-8.2, SI).  Using 
FP, thanatin-BDP-FL binds to LptD/EHis with a Kd of 34±5 nM, whereas thermophoresis 
binding assays gave a Kd of 44±27 nM (see section-10, SI). Thanatin therefore binds in vitro 
to both LptA and LptD/E in the low nanomolar range. 
 In order to characterize the epitope on LptA involved in binding to thanatin, complex 
formation was monitored by [15N, 1H]-HSQC NMR spectroscopy, using a recently described, 
non-aggregating, truncated derivative of LptA called LptAm, lacking the last C-terminal ß-
strand (10). We confirmed in vitro that thanatin binds with the same high affinity also to 
LptAm (see section-9, SI). Therefore, the lack of the last C-terminal ß-strand in this LptAm 
construct, which is important to prevent unwanted aggregation, does not affect binding to 
thanatin. This result is understandable, as we show later that thanatin interacts with the N-
terminal ß-strands of LptA (vide infra).  [15N, 1H]-HSQC spectra revealed complete and 
stable complex formation in the slow exchange regime on the NMR time scale upon addition 
of thanatin to [15N]-LptAm to ca. 1:1.2 molar ratio (see section-11, SI). Free LptAm and the 
complex of LptAm with thanatin displayed a high-quality [15N,1H]-HSQC spectrum with good 
signal dispersion, indicating that the protein-peptide complex was well folded and probably 
rich in β-sheet. While many 1H-15N correlations in [15N]-LptAm were unchanged upon thanatin 
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binding, a multitude of other cross-peaks showed significant chemical shift perturbations 
(CSPs, see section-11, SI). The structure of the thanatin-LptAm complex (Figure 4A) was 
then determined by multidimensional NMR methods using mixtures of unlabeled and 
[13C,15N]-labeled forms of thanatin and LptAm in isotope-edited/filtered NOESY experiments. 
 In the complex, the N-terminal strand of the thanatin ß-hairpin (Pro7-Asn12) docks in a 
parallel orientation onto the first ß-strand in the ß-jellyroll of LptAm (Pro35-Ser40), with the 
strand orientation being clearly defined by multiple interstrand NOEs (Figure 4B). Following 
the ß-turn in thanatin (Arg13-Gly16), the C-terminal strand (Lys17-Met21) is mostly solvent 
exposed (Figure 4A,C), although the side-chain of Met21 nestles into a hydrophobic site on 
the surface of LptAm. Hydrophobic residues on the thanatin N-terminal ß-strand, in particular 
Ile8 and Tyr10, are buried in the hydrophobic interior of the ß-jellyroll (Figure 4A), in a cavity 
formed by LptAm side chains Ile38, Leu45, Val52, Phe54, Val74, Ile86, as evidenced by a network 
of NOEs seen in NOESY spectra. It seems likely that multiple van der Waals contacts and a 
pi-pi stacking interaction (Than.Tyr10-LptAm.Phe54) made between these residues may help 
to stabilize the complex. Moreover, aliphatic residues of thanatin (Val6, Pro7) pack against 
Pro35 and Ile36 near to the N-terminus of LptAm thereby forming another hydrophobic 
interaction, which helps to establish the orientation of the N-terminal part of thanatin. This 
interaction affects the orientation of the short N-terminal helix in LptAm including Asp31, which 
in turn packs against a loop of the ß-jellyroll containing Gln62 (Figure 4C). This proximity 
might explain why mutations at Asp31/Gln62 in LptA have a strong influence upon thanatin 
binding (vide supra). In addition, the N-terminus of thanatin displays NOE contacts with 
residues from the loop of the opposite side of the ß-jellyroll (Gly78-Gly82). This loop is missing 
in the X-ray structure of free LptA (9) likely due to its flexibility. Finally, the side chains of 
thanatin Asn12 and Arg13 are likely involved in hydrogen bonding and formation of 
electrostatic interactions with LptAm, respectively. The amide side chain protons of Asn12, 
whose resonances are significantly downfield shifted in complex with LptAm, are in a suitable 
geometry to form hydrogen bonds with the backbone carbonyl oxygen atoms of Ser40 and 
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Asp41. The guanidinium groups of Arg13 and Arg14 in thanatin are within salt bridge distances 
to carboxylate groups in LptAm (Than.Arg13-LptAm.Glu39, Than.Arg14-LptAm.Asp41).  
 It has been shown that LptA can form head-to-tail homodimers in vivo, although it 
remains possible that a single LptA molecule can bridge the periplasm by contacting both 
LptC and N-LptD (Figure 1) (7). Furthermore, the known crystal structure of an LptA head-to-
tail oligomer (PDB 2R1A) clearly reveals the N-terminal ß-strands of one subunit interacting 
with the C-terminal strands of the next LptA subunit (9). This interaction is likely important in 
assembling the LptA protein bridge across the periplasm in the macromolecular Lpt complex 
(Figure 1A). In addition, the N-terminal strands of LptA mediate binding of LptA to membrane 
anchored LptC (Figure 1) (7, 9, 29, 30). The NMR structure of LptA complexed with thanatin, 
reported here, superimposed upon the crystal structure of the LptA head-to-tail oligomer 
(PDB 2R1A), reveals that the thanatin binding site overlaps and would therefore block the 
interaction between LptA subunits (Figure 4D). It also seems likely that thanatin will inhibit 
the LptA/C protein-protein interaction. Finally, the C-terminal strands of LptA bind to the N-
terminal ß-strands in the periplasmic ß-jellyroll domain of LptD. It is intriguing that the 
structure of the N-terminal ß-strands of the ß-jellyroll in LptD are highly similar to those in 
LptA (14, 15). Indeed, residues in LptA that contact thanatin in the complex are highly 
conserved in the same positions in LptD (see section-11, in SI). This strongly suggests that 
thanatin should interact with the N-terminal ß-strands in the ß-jellyroll of LptD/E. This implies 
that thanatin should also inhibit the interaction of LptA with LpD. Reported affinities of the 
LptA/LptA and LptA/LptC interactions have Kds in the low micromolar range (8, 31). The 
nanomolar affinity of thanatin to both LptA and LptD reported here, therefore, appears strong 
enough to inhibit multiple protein-protein interactions required for assembly of the LPS trans-
periplasmic protein complex. 
 These results highlight a new paradigm for an antibiotic action, targeting a dynamic 
network of protein-protein interactions required for assembly of the Lpt complex in E. coli. 
The results also identify one naturally occurring peptide as a starting point for the 
development of potential clinical candidates that target dangerous Gram-negative bacterial 
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pathogens. Finally, this work may also contribute to a better understanding of the biological 
function of thanatin in its natural context, in controlling titres of symbiotic or invading 
bacterial pathogens in the mid-gut of various insect species (32). 
 
MATERIALS AND METHODS 
 
Peptide synthesis 
Methods of synthesis and analytical data for all peptides are included in the Supplementary 
Information (SI). 
 
Methods for fluorescence and electron microscopy 
Methods for fluorescence microscopy and transmission electron microscopy have been 
described in detail previously (24). 
 
Photoaffinity labeling 
E. coli ATCC25922 cells grown in MH-I broth (50 mL) to an OD600 of 1.0 were collected, 
washed once and taken up in PBS (50 mL) and incubated for 30 min at 37 °C with shaking 
at 200 rpm in the dark with 2-10 μg/ml thanatin-PAL5. Photoactivation was achieved by UV 
irradiation at 350 nm in a Rayonet Reactor (16 x 8W Sylvania blacklight lamps) for 30 min at 
30 °C. Cells were then collected and washed two times with PBS. Cell pellets can be stored 
at -20 °C. The cell pellet was resuspended in 50 mM Tris-HCl, pH 7.3, with protease inhibitor 
cocktail (cOmplete™ Roche) and lysed by three cycles of sonication using a Branson digital 
sonifier equipped with a microtip (80 W, 30% intensity, 20 s on with 20 s off for 2 min) under 
cooling on ice. To remove unbroken cells and cell debris, the lysate was centrifuged (30 min 
at 4’000 rpm, 4 °C). The supernatant was subjected to ultracentrifugation (200’000 g, in a 
Sorvall T-875 rotor, 1 h, 4 °C). The pellet was washed with 50 mM Tris-HCl, pH 7.3 and 
collected again by ultracentrifugation (1 h, 4 °C). 
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Identification of photolabeled proteins by mass spectrometry 
Photolabeled and PBS-washed E. coli were lysed in 50 mM ammonium bicarbonate (AmBic) 
containing protease inhibitor cocktail (Roche, cat: 11704900) and 0.1 % RapiGest (Waters, 
cat: 186002122) by six intervals of 30 s ultrasound sonication in a vial tweeter (Hielscher 
Ultrasonics GmbH) at a power of 170 W and 80% cycle time. Protein concentration was 
determined by Nanodrop 2000 Spectrophotometer (Thermo Fisher Scientific Inc.) and 10 mg 
protein was incubated with 200 µl streptavidin agarose resin (Thermo, cat: 53116) for 100 
min at 4 °C to bind biotinylated proteins. Beads were settled by centrifugation at 2000 g for 5 
min and transferred to Mobicol columns equipped with a 30 μm pore size filter (MoBiTec 
GmbH). Beads were extensively washed with 5 M NaCl, StimLys buffer (50 mM Tris pH 7.8, 
137 mM NaCl, 150 mM Glycerol, 0.5 mM EDTA, 0,1 % Triton X-100, 100 mM NaHCO3 and 
AmBic) to remove non-biotinylated proteins. Bead-bound proteins were reduced with 5 mM 
Tris(2-carboxyethyl)phosphine in AmBic for 40 min at 37 °C, alkylated with 10 mM 
iodoacetamide in AmBic for 30 min at 37 °C and proteolytically digested by sequencing 
grade modified trypsin (Promega, cat: V511A) at an enzyme to protein ratio of 1:100 for 20 h 
at 37 °C. Released peptides were acidified and subjected to C18 purification using 
UltraMicroSpin Columns (The Nest Group).  
 Peptide samples were separated by reversed-phase chromatography on a high-
performance liquid chromatography (HPLC) column (75-μm inner diameter, New Objective) 
that was packed in-house with a 15 cm stationary phase (ReproSil-Pur C18-AQ, 1.9 
micrometer) and connected to a nano-flow HPLC with an autosampler (EASY-nLC 1000, 
Thermo Scientific). The HPLC was coupled to a Q-Exactive plus mass spectrometer 
(Thermo Scientific) equipped with a nano electrospray ion source (Thermo Scientific). 
Peptides were loaded onto the column with 100% buffer A (99.9% H2O, 0.1% FA) and eluted 
at a constant flow rate of 300 nl/min with a 30 min linear gradient from 6–20% buffer B 
(99.9% MeCN, 0.1% FA) followed by a 15 min transition from 20 to 32% buffer B. 
Electrospray voltage was set to 2 kV, sheath and auxiliary gas flow to zero and capillary 
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temperature to 250 °C. In data-dependent acquisition (DDA) mode the mass spectrometer 
automatically switched between precursor and fragment ion detection. Following a high-
resolution survey mass spectrum (from 300 to 1,500 m/z) acquired in the Orbitrap with 
resolution R = 70,000 at m/z 200 (automatic gain control target value 3*106), the 15 most 
abundant peptide ions with a minimum intensity of 2.5*104 were selected for subsequent 
HCD fragmentation with an isolation window of 1.4 Da and fragments were detected by 
MS/MS acquisition in the Orbitrap at resolution R = 35,000 (automatic gain control target 
value 1*106). Target ions already selected for fragmentation were dynamically excluded for 
30 seconds.  
 Acquired raw files were subjected to protein identification using Comet (v.2015.01) 
and Trans Proteomic Pipeline v.4.7 (SPC/ISB Seattle) by matching ion spectra acquired in 
DDA mode against a SwissProt (UniProt consortium) reviewed E. coli protein database 
(downloaded Nov. 2016). Peptides were required to be fully tryptic with a maximum of 2 
missed cleavage sites, carbamidomethylation as fixed modification and methionine oxidation 
as a dynamic modification. The precursor and fragment mass tolerance was set to 20 ppm 
and 0.02 Da, respectively. Identified proteins were quantified by integration of 
chromatographic traces of peptides using Progenesis QI v.2.0 (Nonlinear Dynamics, UK). 
Contaminant hits were removed and proteins filtered to obtain a false discovery rate of < 1%. 
Raw protein abundances based on non-conflicting peptides were exported and differential 
abundance testing was performed using R-package MSstats v3.5.3 (33). Significantly 
enriched E. coli proteins (abundance fold change ≥ 2 and adjusted p-value ≤ 0.05) were 
considered as bona fide Thanatin-PAL5 binding candidates. Mass spectrometric data were 
deposited to the ProteomeXchange Consortium (http://www.proteomexchange.org/) via the 
PRIDE partner repository (data set identifier: PXD-XXXX) (to be deposited upon publication). 
 
Thanatin-resistant E. coli mutants 
E. coli ATCC25922 was grown in MH-II broth (20 mL) to OD600nm=1 at 37°C with 200 rpm 
shaking. This bacterial culture (100 µL, corresponding to ≈5x107 colony forming units) was 
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plated onto MH-II agar plates containing 10-50 µg/mL thanatin and incubated at 37 °C 
overnight.  Growing colonies were then passaged at least four times over MH-II plates 
without selection on thanatin, and then MIC values against thanatin were determined. Two 
independent experiments were performed. Of the initial 10 isolates, the mutants ThanR-2, 
ThanR-4, ThanR-8, ThanR-9 and ThanR-10 exhibited stable resistance (MIC ≥64 µg/mL), and 
in each the lptA gene was sequenced, which revealed mutations Q62L or D31N in the 
primary sequence of the protein (Table S2). The antimicrobial activity of thanatin and seven 
standard antibiotics against the three selected mutants (ThanR-2, ThanR-4 and ThanR-8) are 
shown in Table S3.  
 The complete genomes of three selected mutants (ThanR-2, -4 and -8) as well as the 
wt (ATCC25922) strain used in these studies were sequenced using the Illumina MiSeq 
platform (MiSeq Reagent Kit v2, 500-cycles). Briefly, genomic DNA (gDNA) of the wt and the 
selected mutants was extracted using the Sigma NA2100 1Kit. One microgram of gDNA was 
sheared to 500 bp by sonication (Covaris). DNA fragments were further processed with the 
NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB #E7645S/L). Genome mapping and 
identification of genetic variants was performed using CLC Genomics Workbench 
10.1.1(CLC bio). The genes mutated in the resistant strains, compared to the wt, are shown 
in Table S4. In the ThanR-8 resistant strain, only a single bp change was found in the entire 
genome, in the lptA gene, corresponding to a Q62L change in the primary sequence of the 
protein. 
 
Binding and NMR studies and structure determination of thanatin-LptAm 
complex 
Production of LptA-His6, LptAm, LptD/E  and thanatin in E. coli and details of binding assays 
with LptA by fluorescence polarization and thermophoresis are described in the SI (sections-
8-10). 
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 Production of [15N]- and [15N,13C]-labelled LptAm was performed in BL21(DE3) E. coli 
cells grown in M9 minimal medium appropriately supplemented with 15NH4Cl and 13C-
glucose at 25 °C overnight. Purification is described in SI (section-8). The addition of 20 mM 
CHAPS to the sample buffer significantly improved the quality of the [15N,1H]-HSQC spectra 
by reducing line-broadening effects due to aggregation (see Figures S8 and S9). Final NMR 
samples contained 50 mM sodium phosphate, 150 mM NaCl, pH=7.5 and protein/peptide 
concentrations of 0.5-0.6 mM. 
 NMR spectra were acquired at 290 K (free 15N-thanatin) and at 308 K (free 15N,13C 
LptAm and complex of LptAm:thanatin) using 700- and 600-MHz Bruker Neo spectrometers. 
All spectra were processed using Topspin 4.0 and analyzed using Cara and CCPNmr. The 
1H, 15N, and 13C chemical shifts of backbone and side chain atoms were assigned using a 
standard set of triple resonance experiments on either uniformly 15N,13C-labeled LptAm with 
or without unlabeled thanatin, or with uniformly 15N,13C-labeled thanatin with or without 
unlabeled LptAm at protein concentrations of 0.5-0.6 mM. The LptAm-thanatin complex was 
prepared at a ratio of 1:1.2.   
 Backbone assignment was initiated from manually picked [15N,1H]-HSQC spectra that 
served as anchoring points for HNCO, HN(CO)CACB and HNCACB experiments (34).  
Sequential resonance assignments used the standard strip matching procedure for Cα/Cβ 
chemical shifts. Backbone and side-chain chemical shift assignments were obtained for 
89.7% and 85.7% of residues 28-143 of LptAm and 92.7% and 96.6% of residues 1-21 of 
thanatin, respectively. We noticed that resonances from the presumably unstructured C-
terminal tail including the His-Tag (residues 144-170) as well as some residues in the longer 
loop regions (β6-β7) were often missing, likely due to accelerated amide proton exchange at 
pH 7.5. To this end, we adjusted the sample of the LptA:thanatin complex to pH 4.6, and re-
measured the triple-resonance spectra. The overall signal dispersion in the [15N,1H]-HSQC 
spectra was not changed significantly, indicating a stable complex formation under those 
conditions. Additional amide cross peaks could be assigned to residues located in solvent-
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exposed loops or strands, namely Gly30, Gln43, Met47, Gly78, Asp101 and Asp139. Many more 
peaks became visible, that were often characterized by negative values of the 15N{1H}-NOEs 
indicating that they belonged to flexible amide moieties, but that could not be assigned 
unambiguously.  
 Hβ and Hα chemical shifts obtained from the HBHA(CO)NH experiment were used in 
combination with Cα/Cβ chemical shifts from the backbone assignments to obtain sidechain 
assignments in HCCH experiments. The aromatic sidechains were linked to the backbone 
using the (HB)CB(CGCDCD)HD and (HB)CB(CGCDCDCE)HE experiments (35). The 
assignment of thanatin resonances in the complex was performed in a similar manner. 
Proton chemical shifts were referenced to the water line at 4.65 ppm at 308 K, from which 
the nitrogen and carbon scales were derived indirectly by using the conversion factors of 
0.10132900 (15N) and 0.25144954 (13C). All chemical shifts were deposited in the BMRB 
database under ID 34261. 
 Upper-distance restraints used for the structure calculations of the LptAm:thanatin 
complex were generated from 70 ms 15N- and 13C-NOESY (aliphatic and aromatic carbons) 
spectra. Intermolecular restraints were obtained from 70 ms 13C,15N-filtered/13C-edited 
(aliphatic & aromatic 13C) and 13C,15N-filtered/15N-edited NOESY spectra, all experiments 
performed on two samples (13C,15N-labled LptAm/unlabelled thanatin and unlabelled LptAm/ 
13C,15N-labelled thanatin.  Additional torsion angle restraints were derived from backbone 
chemical shifts using the program TALOS+ (36). The solution structure of the LptAm:thanatin 
complex was determined using distance restraints derived from a set of NOESY spectra and 
torsion angle restraints derived from TALOS+. A full description of the structure calculations 
and statistical analysis of results are given in the SI. 
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Figures 
Figure 1. LPS Transport pathway and thanatin-based probes. A, The LPS transport 
apparatus in Gram-negative bacteria comprises the seven proteins LptA-G, which form a 
macromolecular complex spanning the IM and OM. LPS transport across the periplasm 
occurs over a bridge formed by one or more copies of LptA. B, structures of thanatin and the 
photoprobe thanatin-PAL5 and fluorescence probe thanatin-BDP-FL. 
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Figure 2.  
Electron and fluorescence microscopy studies. A, B, TEM studies of E. coli 
ATCC25922, before (A) and after (B) thanatin treatment (1.5 µg/mL), showing internal 
accumulations of membrane-like material. Scale bar 500 nm. C-D, Super-resolution 
fluorescence microscopy of E. coli ATCC25922 without (C) or with thanatin (5 µg/mL, D) and 
stained with FM4-64, Sytox-Green, or DAPI. Top the FM4-64 channel (red staining); bottom, 
superimposition of all three channels (with DAPI (blue) and SYTOX-Green (non detected)). 
E (both pictures) E. coli staining with thanatin-BDP-FL (8 µg/mL) for 2 h at 30°C. Cells were 
analyzed using a Leica CLSM SP8 gSTED microscope. Scale bars, 4 µm; or bottom right 10 
μm. For experimental details see Section-4, SI. 
 
 
 
 
 
 
 
 
  
 22 
Figure 3. 
Photolabeling E. coli ATCC25922 with thanatin-PAL5. A, Western blot (biotin detection) 
and corresponding SDS-PAGE (Coomassie blue staining) of membrane protein fraction 
from: Lane-1, control unlabeled cells; Lane-2 and -3, cells photolabeled with thanatin-PAL5 
(10 µg/mL and 2 µg/mL); Lane-4, cells photolabeled with thanatin-PAL5 (10 µg/mL) + 
competitor thanatin (200 µg/mL). B, Western blot and SDS-PAGE after photolabeling with 
thanatin-PAL5 (2 µg/mL) with (+) or without (-) reduction of extracted membrane proteins 
with DTT. C, Volcano Plot showing relative abundance of E. coli proteins in thanatin-PAL5 
labeled versus unlabeled control sample after streptavidin pulldown detected by MS-based 
proteomic analysis. Significantly enriched proteins (right/above dotted lines) are highlighted 
in green and represent PAL5-labeled proteins. 
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Figure 4.  
The solution structure of the LptAm-thanatin complex. (A) Ribbon representation of a 
single NMR LptAm-thanatin complex in two different orientations. LptAm and thanatin are in 
green and red, respectively. The flexible C-terminus of LptAm encompassing residues 144-
159 and the His-tag are not shown. (B) Structurally relevant intermolecular NOEs between 
backbone atoms of the first β-strands of LptA and thanatin are indicated with dotted arrows, 
and HN-HN and HN-Hα NOEs are colored in blue and green, respectively. (C) Ribbon model 
of the LptAm-thanatin complex. Residues involved in the protein-peptide hydrophobic 
interface (left panel) as well as in hydrogen bonding and electrostatic interactions (right 
panel) are indicated by ball-and-stick representation. (D) Superposition of the LptA dimer 
(PDB 2R1A, chains B (light blue) and C (violet) with the LptAm-thanatin complex (green/red). 
Thanatin occupies a binding site on LptAm which is used to mediate LptA-LptA interactions 
needed to form the periplasmic bridge connecting inner and outer membranes for LPS 
transport. 
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1.  Bacterial strains and plasmids used in this study 
 
Table S1. Bacterial strains and plasmids used in this study. 
  
Bacterial strains used in this study   
E. coli ATCC25922 ATCC strain collection 
E. coli XLI blue ATCC strain collection 
E. coli ML35 (ATCC 43827) ATCC strain collection 
E. coli BL21 (DE3) Novagen 
E. coli K12 MG1655 (ATCC 47067) ATCC strain collection  
 
Plasmids used in 
this study description reference 
pET3a - Novagen 
pUC19 - 
New England 
Biolabs 
pET22b - Novagen 
pOCI1548 lptA (1-185) NdeI/XhoI in pET22b this study 
pOCI1551 lptA (1-185, Q61L) NdeI/XhoI in pET22b this study 
pOCI1551 lptA (1-185, D31N) NdeI/XhoI in pET22b this study 
pET3a::lptAm 
lptA (1-159) with C-terminal hexahistidine tag 
NdeI/BamI in pET3a this study 
pEMBT2 -  (37) 
pEMBT2_thanatin gene coding for Thanatin  SapI/BamHI in pEMBT2 this study 
pET3a::lptD lptD NdeI/BamHI in pET3a this study 
pCDFduet-1 - Novagen 
pCDF::lptE-His6 
lptE with C-terminal hexahistidine tag NcoI/XhoI in 
pCDFduet-1 this study 
 
 
 
2. Peptide Synthesis  
 
Thanatin was synthesized by solid-phase peptide synthesis using standard Fmoc-chemistry, 
using the method described by Fehlbaum et al. (17). The disulfide bond was introduced by 
air oxidation in 0.1 M ammonium acetate buffer at pH 8.5. Crude peptide was purified by 
reverse phase HPLC (Agilent C18 column, 21.2 x 250 mm, 7 µm) using a binary gradient 
from 10 to 50% MeCN/H2O with additional 0.1% TFA on an ÄKTA purifier 100 system 
(Amersham Biosciences). UPLC analysis was performed on an ACQUITY UPLC® system 
(Waters) equipped with a BEH130 C18 column, 2.1 x 100 mm, and 1.7 μm particle size at a 
gradient of 5 to 95% MeCN/H2O with additional 0.1% TFA at 40°C. Enantiomeric D-thanatin 
was synthesized in the same way with D-amino acids. High resolution ESI-MS: m/z 
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487.4620 [M+5H]5+ (native thanatin), m/z 487.4635 [M+5H]5+ (D-thanatin), calc. mass 
487.4616 [M+5H]5+. 
 
Synthesis of the photoprobes thanatin-PAL5 and thanatin-PAL7 
 
The route used for synthesis of thanatin-PAL5 and thanatin-PAL7 is illustrated in Scheme 
S1, with thanatin-PAL5 as an example. 
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Scheme S1.  Synthesis of thanatin-PAL5. The linear peptide was assembled by solid-phase peptide synthesis 
on chlorotrityl chloride resin using Fmoc chemistry. The synthesis of Fmoc-photoproline has been described 
elsewhere (25, 26). Resin-bound, side-chain protected linear peptide is shown, and was converted into thanatin-
PAL5 in two steps: a) (i) Piperidine:DMF (1:3); then (ii) Biotin-PEG4-COOH (Broadpharm), HATU, HOAt, DIPEA, 
DMF. b) (i) TFA:EDT:thioanisole:H2O:TIS (75:10:10:4:1), then (ii) oxidation by air in 0.1 M ammonium acetate 
buffer, pH 8.5. Abbreviations:  HATU, 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-
phosphate; DMF, dimethylformamide; HOAt, 1-Hydroxy-7-azabenzotriazole; DIPEA, diisopropylethylamine; TFA, 
trifluoroacetic acid; EDT. ethanedithiol; TIS, triisopropylsilane. 
 
Incorporation of Fmoc-L-photoPro was performed according to published procedures (26). 
The linear thanatin sequence was synthesized as described above and then commercially 
available biotin-PEG4-COOH (Broadpharm, Scheme S1) was coupled on-resin under 
standard conditions with HATU/HOAt. The peptide was then cleaved from the resin, 
deprotected, oxidized, and purified by preparative HPLC, as described above. After 
purification by HPLC, the purity of thanatin-PAL5 (>95%) was confirmed by UPLC and its 
identity by HR-ESI m/z (calc.) 587.3041 [M+5H]5+, m/z (exp.) 587.3041 [M+5H]5+. The 
sample showed antimicrobial activity against E. coli ATCC25922 (MIC of 2-4 μg/mL). 
 
Synthesis of the fluorescent probe thanatin-BDP-FL 
 
The fluorescent probe thanatin-BDP-FL was synthesized following Scheme S2. The linear 
thanatin sequence was synthesized on chlorotrityl chloride resin as described above. 
Commercially available propargyl-PEG4-COOH (Broadpharm) was then coupled on-resin 
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under standard conditions with HATU/HOAt. After cleavage from the resin, deprotection, 
oxidation, and purification of the intermediate by preparative HPLC, BDP-FL-azide 
(Lumiprobe) was coupled by "click" chemistry (38). For this, the thanatin-PEG4-alkyne 
intermediate (8.9 mg, 0.0033 mmol) was dissolved in H2O (500 µl). Sodium ascorbate (35 µl, 
0.1 M, 0.0035 mmol), BDP-FL-azide (0.0013 mmol, 0.25 mg) dissolved in DMSO (100 µl), 
and CuSO4 (35 µl, 0.1 M, 0.0035 mmol) were sequentially added under stirring. After 30 min, 
the reaction mixture was injected directly on a preparative HPLC C18 column with a gradient 
of 10-50% MeCN/H2O with additional 0.1% TFA. The isolated fraction was lyophilized 
yielding 4 mg (98%) of red lyophilisate. High resolution ESI-MS: m/z 763.1505 [M+4H]4+ 
(Thanatin-BDP-FL) calc. mass 763.1500 [M+4H]4+. The enantiomer D-thanatin-BDP-FL was 
made in exactly the same way using D-amino acids. HR-ESI-MS: m/z 763.1501 [M+4H]4+. 
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Scheme S2. Synthesis of thanatin-BDP-FL. The linear peptide was assembled by solid-phase peptide 
synthesis on chlorotrityl chloride resin using Fmoc chemistry. a) (i) Piperidine:DMF (1:3), then (ii) propargyl-
PEG4-COOH (Broadpharm), HATU, HOAt, DIPEA, DMF. b) (i) TFA:EDT:thioanisole:H2O:TIS (75:10:10:4:1), then 
(ii) oxidation by air in 0.1 M ammonium acetate pH 8.5. c) BDP-FL-azide (Lumiprobe), CuSO4, sodium ascorbate, 
DMSO:H2O (1:5). 
 
 
L-Thanatin-BDP-FL showed good antimicrobial activity against E. coli ATCC25922 (MIC of 
1- 2 μg/mL). 
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Synthesis of the fluorescent probe thanatin-Cy3 
The intermediate thanatin-PEG4-alkyne (9.3 mg, 0.0035 mmol) (Scheme S2, after step-b) 
was dissolved in H2O (500 µl), and sodium ascorbate (0.1 M, 35 µl, 0.0035 mmol), Cy3 
azide (Lumiprobe, 0.00174 mmol, 1 mg) dissolved in 100 µl DMSO and CuSO4 (0.1 M, 35 µl, 
0.0035 mmol) were added (Scheme S3). After 15 min the reaction mixture was injected 
directly on a preparative HPLC C18 column with a gradient of 20-60% MeCN/H2O (0.1% 
TFA). The isolated fraction was lyophilized yielding 2.3 mg (41%) of purple lyophilisate. High 
resolution ESI-MS: m/z 643.5538 [M+5H]5+ (Thanatin-Cy3), calc. mass 643.5531 [M+5H]5+. 
 
 
Scheme S3. Structure of thanatin-Cy3. 
 
The enantiomer, D-thanatin-Cy3, was made in exactly the same way using D-amino acids. 
HR-ESI-MS m/z 643.5528 [M+5H]5+. 
 
3. Permeabilization of the E. coli cell envelope 
 
E. coli with thanatin and Sytox-Green   
E. coli ATCC25922 was grown in Mueller-Hinton-I (MH-I) broth at 37 °C to an OD600 of 0.3-
0.4. The cells were then centrifuged (5 min at 4000 rpm) and the pellet was resuspended in 
MH-I to an OD600 of 0.1. This culture was placed into a UV cuvette containing a magnetic 
stirring bar and 0.002% (w/v) of Polyoxethylene80 (Tween80). The fluorescence was 
recorded using an LS55 Fluorescence Spectrometer (PerkinElmer). Excitation and emission 
wavelength for Sytox-Green dye are 488 nm and 525 nm respectively. After 100s, Sytox 
Green dye (0.5 μM) was added from a stock solution (500 μM) in DMSO. After 400 s the 
antibiotic was added (arrow in Figure S1) and the fluorescence intensity was recorded. The 
effects of adding thanatin, polymyxin B and water (as control) are shown in Figure S1. At the 
same time the OD600 values were recorded at the start and end of the experiment. All 
measurements were performed in triplicate (error bars shown). 
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Figure S1. Membrane permeabilization monitored by uptake (or absence thereof) of 
SYTOX-Green. No fluorescence increase is seen from cells in the presence of thanatin and 
SYTOX-Green, or cells alone. The change in cell density (OD600) in the cuvette over 1 h is 
shown on the right side. Note that substantial inhibition of growth is seen in the presence of 
thanatin at 100 µg/mL. 
 
Release of ß-lactamase or ß-galactosidase from E. coli cells 
A, Release of ß-lactamase from the periplasm was monitored using the substrate CENTA 
(Merck-Millipore, 180 µM) with E. coli ML35::pET3a grown in MH-II broth at 37 °C and 
resuspended in PBS with CaCl2 (1 mM) and MgCl2 (0.5 mM) and BSA (0.02% w/v). 
Hydrolysis of CENTA is monitored at 405 nm after addition of protegrin I, thanatin or 
ciprofloxacin at the concentrations shown (Figure S2, A). The green dashed lined is 100% 
lysis by sonication. B, Release of ß-galactosidase from the cytoplasm was monitored using 
the substrate O-nitrophenyl-ß-D-galactoside (250 µM) with E. coli ML53::pET3a grown in LB 
medium at 37 °C and resuspended in PBS with CaCl2 (1 mM) and MgCl2 (0.5 mM), and the 
antibiotics at the concentrations shown (Figure S2, B). All measurements were performed in 
triplicate (error bars shown). 
 
 
Figure S2. Release of ß-lactamase (A) and of ß-galactosidase (B) in the presence of 
antibiotic monitored by enzymic assays. Note that thanatin (and ciprofloxacin, as control) 
does not cause detectable release of either enzyme from cells, whereas protegrin I caused 
complete release of both enzymes (100% value corresponds to enzyme released by 
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sonication of cells). 
 
4. Macromolecular synthesis assays 
 
Macromolecular synthesis assays 
The incorporation of radioactively labelled precursors ([3H]-thymidine (80 Ci/mmol), L-[3H]-
leucine (108 Ci/mmol), [3H]-uridine (30 Ci/mmol) or N-[3H]-acetyl-glucosamine (30 Ci/mmol) 
into macromolecules (DNA, protein, RNA, or cell wall) in E. coli ATCC25922 was measured 
in chemically defined medium in a microplate format at various thanatin concentrations (39). 
Labelling was performed using exponentially growing cells at OD600 of 0.3 for 20 min. The 
incorporation of radioactivity relative to a control (no antibiotic) is shown in Figure S3. The 
experiment was performed in triplicate, and results from each experiment are shown. 
 
 
Figure S3. Relative incorporations of 3H label from labelled precursor over 20 min, at 37 °C, 
performed in triplicate. The results show no inhibition of protein, RNA or DNA biosynthesis, 
but a slight stimulation of incorporation of N-[3H]-acetylglucosamine, most likely into LPS, 
peptidoglycan or into polysaccharide capsule. In control experiments, the expected effects of 
known antibiotics inhibiting protein, DNA or RNA biosynthesis were observed (not shown). 
 
 
5. Methods for fluorescence and electron microscopy 
 
Methods for fluorescence microscopy and transmission electron microscopy have been 
described in detail previously (24). 
 
 
6. Photoaffinity labeling 
 
Detection of photolabeled proteins by Western blotting 
 
Membrane protein fractions in SDS loading buffer containing DTT (100 mM) were boiled for 
5 min at 100°C before SDS-PAGE under standard Laemmli conditions. Proteins were blotted 
to PVDF membrane (0.45 μm pore size, Immobilon®-P, Merck) using a 1:1 mixture of Tris-
glycine-SDS (12 mM Tris, 96 mM glycine, 0.1% SDS) and phosphate-SDS-urea buffer (10 
mM Na2HPO4, 1% SDS, 6 M urea). Blotting of proteins from gel onto the membrane was 
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achieved using a Pierce G2 Fast Blotter (Thermo Fisher) for 2 h at 0.5 A and 10 V. For 
chemiluminescence detection, the blocked membrane was incubated with Streptavidin-HRP 
or NeutrAvidin-HRP conjugate (Pierce, diluted 1:30'000 in PBS, 1% BSA, 0.2% Tween20) 
for 1 h. The membrane was washed 4 x 5 min with PBS and developed with 
WesternBright™ Sirius™ (Advansta) HRP substrate. Chemiluminescence was detected on a 
ChemiDoc™ MP Imaging System (Bio-Rad) over the course of 1-20 min. 
 
 
7. Thanatin-resistant E. coli mutants 
 
Of the initial 10 isolates (see text), the mutants ThanR-2, ThanR-4, ThanR-8, ThanR-9 and 
ThanR-10 exhibited stable resistance (MIC ≥64 µg/mL), and in each the lptA gene was 
sequenced, which revealed mutations Q62L or D31N in the primary sequence of the protein 
(Table S2). The antimicrobial activity of thanatin and seven standard antibiotics against the 
three selected mutants (ThanR-2, ThanR-4 and ThanR-8) are shown in Table S3. 
 
Table S2. ThanR isolates from two independent passaging experiments, with MICs against 
thanatin after 4 generations without selection pressure, together with point mutations 
detected by lptA sequencing. 
 
 
Table S3. MIC values (µg/mL) of three selected mutants (ThanR-2, ThanR-4 and ThanR-8) 
and wt, against thanatin and seven standard antibiotics (colistin, erythromycin, gentamycin, 
vancomycin, rifampicin, ampicillin and ciprofloxaxin). 
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The genomes of ThanR-2, ThanR-4  and ThanR-8 were determined by genome sequencing. 
Mutations detected in the resistant strains, compared to the wt, are shown in Table S4. In 
the ThanR-8 resistant strain, only a single bp change was found in the entire genome, in the 
lptA gene, corresponding to a Q62L change in the primary sequence of the protein. 
 
 
Table S4. Genes mutated in the mutant strain compared to wt (+ indicates a mutation, - 
indicates no mutation in the selected gene). Gene identifier and description were extracted 
from the GenBankfile CP009072. 
 
 
For complementation experiments, genes encoding LptA with the corresponding mutations 
(Q62L-LptA-His6 and D31N-LptA-His6) were cloned into pET22b to give pOCI1551 or 
pOCI1552, respectively, with the empty pET22b plasmid and the plasmid containing the 
wild-type LptA-His6 (pOCI1548) as controls. The plasmids were introduced into E. coli 
ATCC25922 or K12 MG1655. MIC values against thanatin show that both LptA mutants 
confer protection in both strains (Table S5). 
 
 
Table S5.  Antimicrobial activities of thanatin (MIC, µg/mL) against E. coli wt strains, and 
strains containing plasmids shown. 
 
8. Production of LptA-His6, LptAm, LptD/E  and Thanatin in E. coli 
 
8.1. Production of E. coli LptA-His6 and LptAm 
The primary sequence of LptA in E. coli K12 MG1655 as well as ATCC25922 is: 
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  1 MKFKTNKLSL NLVLASSLLA ASIPAFAVTG DTDQPIHIES DQQSLDMQGN VVTFTGNVIV         
 61 TQGTIKINAD KVVVTRPGGE QGKEVIDGYG KPATFYQMQD NGKPVEGHAS QMHYELAKDF       
121 VVLTGNAYLQ QVDSNIKGDK ITYLVKEQKM QAFSDKGKRV TTVLVPSQLQ DKNNKGQTPA       
181 QKKGN  
 
green, signal peptide;  blue, segment removed in LptAm.  
 
The lptA gene from E. coli ATCC25922 was amplified by PCR using primers Ndefor and 
Xhorev (Table S6) and cloned into NdeI/XhoI sites in the plasmid pET-22b to give pOCI1548 
encoding LptA-His6. 
 
 
 
 
 
Table S6. Sequences of primers used for cloning experiments. 
 
The primary sequence of expressed LpA-His6 (linker in red followed by His6-tag) is shown 
below: 
 
28  VTGDTDQPIH IESDQQSLDM QGNVVTFTGN VIVTQGTIKI NADKVVVTRP GGEQGKEVID  
88  GYGKPATFYQ MQDNGKPVEG HASQMHYELA KDFVVLTGNA YLQQVDSNIK GDKITYLVKE  
148 QKMQAFSDKG KRVTTVLVPS QLQDKNNKGQ TPAQKKGNLE HHHHHH  
 
LptA-His6 was produced in E. coli BL21(DE3) grown in TB with 2% glycerol, induced at 
OD600 of 0.80 with IPTG (0.1 mM) and further growth at 16°C and 200 rpm overnight. LptA-
His6 was purified over a 5 mL Ni-NTA HiTrap column in 50 mM sodium phosphate, pH 8, 
300 mM NaCl, 2% glycerol, 20 mM imidazole, and elution with the same buffer and 300 mM 
imidazole. Further purification using a 6 mL ResourceQ column (in 50 mM sodium 
phosphate, pH 8, 100 mM NaCl, 2% glycerol, 0 - 1 M NaCl) gave LptA-His6 collected in the 
flow-through. Mass analysis of the purified protein by ESI-MS confirmed the expected 
molecular mass and showed that the signal sequence had been removed (m/z (obs.) 
=18360.55, m/z (calc. 18360.55). 
 
A truncated form of lptA (LptAm, ∆160-185) (10) was amplified using the primers Ndefor and 
lptA159SGRVEhis6rev and the product was cloned NdeI/BamHI into pET3a to introduce a 
linker and a His6 tag.  
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The primary sequence of LptAm (linker in red, followed by the His6-tag) is shown below 
(native amino acid numbering) 
 
 30         40         50         60         70 
VTGDTDQPIH IESDQQSLDM QGNVVTFTGN VIVTQGTIKI NADKVVVTRP 
 80         90        100        110        120                   
GGEQGKEVID GYGKPATFYQ MQDNGKPVEG HASQMHYELA KDFVVLTGNA  
130        140        150       159 
YLQQVDSNIK GDKITYLVKE QKMQAFSDKG KRSGRVEHHH HHH 
 
Green, linker; Red, His6 tag 
 
LptAm was produced in LB medium after induction with 0.1 mM IPTG at OD600 of 0.6, 
overnight at 20°C. The purification was performed over a 5 ml Ni-NTA HiTrap column in 50 
mM sodium phosphate, pH 8, 300 mM NaCl, 10% glycerol, 5 mM imidazole and elution with 
500 mM imidazole in the same buffer. Mass analysis of the purified protein by ESI-MS 
confirmed the expected molecular weight and showed that the signal sequence had been 
removed (m/z (obs.) =15870.5, m/z (calc.) =15870.70). 
 
8.2. Production of the E. coli LptD/EHis complex 
 
The LptD/E complex was produced by slight adaptation of published procedures (14, 15, 
40). The E. coli lptD including its native signal sequence was amplified by PCR using 
lptD_Ndefor and lptD_Bamrev primers (Table S6) and cloned NdeI/BamHI into pET3a 
(Novagen) to give pET3a::lptD. Upon expression in E. coli and cleavage of the signal 
peptide, LptD has the native N-terminus (res. 23–784). E. coli lptE was amplified using the 
primers lptE_Ncofor and lptE_His6_Xhorev (Table S6) and cloned into NcoI/XhoI sites in the 
pCDFduet-1 vector (Novagen) with its native signal sequence to give pCDF::lptE-His.  
 Both plasmids were introduced into E. coli BL21(DE3) and coexpression of LptD and 
LptEHis was achieved by selection with carbenicillin and streptomycin. Briefly, a 500 mL 
culture was grown at 26 °C until OD600 0.8, then 0.1 mM IPTG was added and the culture 
was grown at 26 °C for another 22 h. Cells were pelleted by centrifugation at 5000 rpm, 4 °C 
for 30 min and then resuspended in 30 mL TBS (20 mM Tris-HCl, 150 mM NaCl, pH 8.0) 
containing 1 mM EDTA, 2 mM PSMF, and 1 mM benzamidine. The resuspended cells were 
lysed by sonication. The cell lysate was centrifuged at 5’000 rpm, 4 °C for 1 h to remove 
unbroken cells, and the supernatant was centrifuged at 45’000 rpm, 4 °C for 1 h to collect 
the total cell membranes, which were washed with TBS containing 0.5% N-lauroylsarcosine 
(25 mL) at 4 °C for 1 h in order to remove inner membranes. Outer membranes were 
collected by ultracentrifugation at 45’000 rpm, 4 °C for 1 h, extracted with 15 mL TBS-B (20 
mM Tris-HCl, 100 mM NaCl, 20 mM imidazole, pH 8.0) containing 1% anzergent 3–14 at 4 
°C for 2 h, and re-centrifuged as above. 
 The resulting supernatant was loaded onto a 5 mL HisTrap HP column (GE 
Healthcare), which was pre-equilibrated with TBS buffer containing 1% anzergent 3–14 
(TBS-A). The flow through was collected and reloaded onto the column. The column was 
washed with 25 mL TBS buffer containing 0.02% anzergent 3–14 followed by 25 mL TBS 
containing 1% n-octylglucoside (OG) (TBS-B) and then eluted with TBS-C (20 mM Tris-HCl, 
100 mM NaCl, 200 mM imidazole, pH 8.0) containing 1% OG.  
 The eluate was loaded onto a 6 mL Resource Q column (GE Healthcare), which was 
pre-equilibrated with Tris buffer (TB) (20 mM Tris-HCl, pH 8.0) containing 1% OG. The flow 
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through was collected and re-loaded onto the column. The unbound proteins were washed 
out with 24 mL TB containing 1% OG and proteins were eluted by a 180-mL gradient, 0 – 
1000 mM NaCl in TB containing 1% OG. The fractions containing LptD/EHis were pooled and 
concentrated in an ultrafiltration device (Amicon Ultra, 50 kDa cut-off) to about 300 μL, and 
further purified by gel filtration on a prepacked Superdex 200 Increase 10/300 GL column 
(GE Healthcare), using TBS containing 1% OG as the eluent. 
 
The LptD/EHis complex was analyzed by SDS-PAGE, after boiling to dissociate and unfold 
the complex, either with reduction by DTT (lane-2) or without DTT treatment (Figure S4). 
The Coomassie-stained gel shows the characteristic shift in mobility of LptD with the change 
in redox status of the disulfide bonds in LptD (27, 28). 
 
 
Figure S4. SDS-PAGE of purified LptD/EHis complex from E. coli. Left, without reduction of 
disulfide bonds with DTT; right, with reduction with DTT; center, molecular weight markers. 
 
 
8.3. Production of labelled thanatin in E. coli  
In order to produce [13C,15N]-labeled thanatin in E. coli, the gene coding for thanatin was 
synthesized from overlapping primers (Thanatin_SapIfor and Thanatin_BamHIrev, Table S6) 
and cloned into pEM3BT2 (kindly provided by E. Michel (37)). Production of uniformly 
labelled [13C,15N]-thanatin from E. coli BL21 (DE3):pEMBT2_thanatin in M9 minimal medium 
supplemented with 5 g/L 15NH4Cl and 5 g/L 13C glucose was induced at OD600 0.7 with 0.1 
mM IPTG and the cells were grown overnight at 37°C. 
 
After cell lysis the His6-tagged fusion protein GB1-thanatin was purified by IMAC (1mL 
HisTrap cartridge, 50mM Na phosphate, 300mM NaCl, pH 7.5, 20-300mM imidazole). TEV 
cleavage was performed in dialysis using TEV cleavage buffer (50mM Tris pH 7.5, 0.5mM 
EDTA, 1mM DTT) and His-tagged TEV protease (ca. 12mM). Thanatin was collected by Ni-
affinity purification in a washing step with 20mM imidazole. After dialysis in 0.1M ammonium 
acetate, pH 8.5, the oxidized thanatin was purified by C18 reversed phase HPLC (Agilent 
Eclipse XBD-C18) using a gradient of 10 to 50 % acetonitrile in H2O in the presence of 0.1% 
TFA over 5 column volumes. 
 
The composition of the NMR sample was the following: 
380 µM [13C,15N]-thanatin and 1.2 eq LptAm (460 µM in 18 mM sodium phosphate buffer, pH 
7.5, 54 mM NaCl, 20 mM CHAPS, 10% D2O). 
 
Sequence of the resulting GB1-thanatin fusion protein: 
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1  MSGSHHHHHH SSGIEGRGRQ YKLILNGKTL KGETTTEAVD AATAEKVFKQ YANDNGVDGE  
61 WTYDDATKTF TVTESSGENL YFQGSKKPVP IIYCNRRTGK CQRM  
 
(Green, His-tag; blue, GB1; red, thanatin; underlined, TEV cleavage site, between QG) 
 
Cleavage of the fusion protein with tobacco etch virus (TEV) protease and air oxidation gives 
native thanatin. 
 
 
9. Binding assays with LptA by fluorescence polarization and thermophoresis 
 
9.1. Fluorescence polarization (FP) 
FP measurements were recorded on a Safire2 plate reader (Tecan) in black, flat-bottom, 
non-binding 96 well plates (Greiner). Instrument settings were optimized for Thanatin-BDP-
FL (Excit. 470 nm, Emiss. 508 nm) with a bandwidth of 10 nm and a G-factor of 1.21, at 
room temperature. For the synthesis of the probe see Section-2. 
 
Direct assay. In the direct assay a constant concentration of thanatin-BDP-FL (100 nM) was 
titrated with the analyte protein LptA-His6. A 24-fold titration series of LptA-His6 was 
prepared starting from 31 μM to 3.7 pM in buffer (sodium phosphate 50 mM, NaCl 150 mM, 
pH 8.0) and 0.05% Tween20. After incubation for 30 min, FP was recorded (Figure S5A). 
Data were averaged from triplicate experiments and normalized from the concentration point 
with the lowest anisotropy value. Data were fitted to a 1:1 binding model using GraphPad 
Prism by implementing equation E 1, where a = -1, b = Kd + x + Atot and c = -x * Atot. m is the 
amplitude of maximal anisotropy increase, Kd is the dissociation constant and Atot is the total 
ligand concentration. The results (Figure S5A) gave a Kd 12 ± 3 nM for LptA-His6 binding to 
thanatin.  
 
 y = m*((- b + sqrt(b2 - 4*a*c)) / 2*a) / Atot E 1 
   
A                          B     
   
 
 
C                  D   
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Figure S5. A, Direct FP binding assay of thanatin-BDP-FL (100 nM) titrated with the analyte 
protein LptA-His6. Measurements were done in triplicate with standard deviation shown. B,C, 
Competition FP assay. The thanatin-BDP-FL (0.5 µM) and LptA-His6 (0.5 µM) was titrated 
with free thanatin (B), or with enantiomeric D-thanatin (C) (no competition observed). 
Measurements were done in triplicate with standard deviation shown. D, FP assay reveals 
binding of thanatin-BDP-FL (30 nM) to LptAm. Measurements were done in triplicate with 
standard deviation shown. 
 
 
Competition assay. In the competition experiments, a constant concentration of thanatin-
BDP-FL (0.5 µM) and LptA-His6 (0.5 µM) was titrated with free thanatin, or with enantiomeric 
D-thanatin. After incubation for 30 min, FP was recorded (Figure S5B,C). Data were 
averaged from triplicate experiments and normalized from the concentration point with the 
lowest anisotropy value. Data were fitted to a competition binding model using GraphPad 
Prism by implementing methods described elsewhere (41), which gave a Kd for thanatin 
binding of 10 ± 2 nM. 
 
Binding studies were also performed to show that thanatin binds to LptAm. Using the same 
FP method (see above) and LptAm, a Kd for binding to Thanatin-BDP-FL was determined (Kd 
≈ 3.8 ± 1.0 nM) (Figure S5D). 
 
9.2. Thermophoresis binding assays 
The binding of thanatin to LptA-His6 and to LptAm was quantified by Microscale 
Thermophoresis using a Monolith NT.115 instrument (NanoTemper Technologies) with 
hydrophobic capilliaries at room temperature in PBS (sodium phosphate (50 mM), NaCl (150 
mM, pH 8.0), Tween-20 (0.05%). The protein was labeled with Dylight 650-N-
hydroxysuccinimide ester labeling kit (Thermofischer). The results (Figure S6) gave a Kd 20 
± 1 nM for LptA-His6 and 4.0 ± 0.24 nM for LptAm. 
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Figure S6. Binding of thanatin to LptA-Dylight650 (left) and LptAm-Dylight650 (right) by 
Microscale Thermophoresis. Measurements were done in triplicate with standard deviation 
shown. 
 
 
10. Binding assays with LptD/E by fluorescence polarization and 
thermophoresis 
 
The binding of thanatin (and its enantiomer) to LptD/EHis was studied by fluorescence 
polarization using thanatin-BDP-FL and by thermophoresis using thanatin-Cy3 (see Section 
2). 
 
Fluorescence polarization (FP) 
FP measurements were performed on a plate reader (Tecan Safire Spectrometer) equipped 
with a FP module and a filter set for an excitation wavelength of 470 nm and emission of 508 
nm with a band width of 10 nm. The fluorescently labelled thanatin-BDP-FL at 30 nM was 
titrated with LptD/EHis from 1250 to about 0.0003 nM in TBS buffer (20 mM Tris-HCl, 100 mM 
NaCl, pH 8.0) with 1% w/v octylglucoside (OG) at 20 °C. The responses were analyzed 
using a standard Langmuir binding model, which gave a Kd of 34 ± 5 nM (Figure S7A). In 
addition, binding of the enantiomer D-thanatin-BDP-FL was also monitored to LptD/EHis. 
However, FP changes could only be detected with micromolar concentrations of LptD/EHis, 
and the upper plateau of the binding isotherm could not be reached.  We conclude that the 
thanatin retains an ability to bind enantioselectively to the recombinant E. coli LptD/EHis 
complex in vitro. 
 
Thermophoresis 
For thermophoresis studies, the fluorescently labeled thanatin-Cy3 (and its enantiomer) 
were used, with a Monolith NT.115 instrument (NanoTemper Technologies) with premium 
capillaries at RT. The thanatin-Cy3 concentration at 50 nM was titrated with LptD/EHis in TBS 
buffer with 1% OG, pH 8, at RT, from 1000 to 0.06 nM, which gave a low but reproducible 
positive thermophoresis signal (Figure S7B). The responses were analyzed using a 
standard Langmuir binding model, from which an apparent Kd ≈ 44 ± 27 nM was determined. 
The enantiomeric form D-thanatin-Cy3 showed a negative thermophoresis signal, which 
increased into the micromolar range without reaching a stable plateau at the highest 
LptD/EHis concentrations tested. 
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In addition, when thanatin-Cy3 was titrated with LptD/EHis an increase in fluorescence signal 
was observed (Cap scan) (Figure S7C). A Kd was also calculated from the normalized 
fluorescence and found to be 40 ± 8 nM. In contrast, D-thanatin-Cy3 showed an increase in 
fluorescence upon binding to the protein only at micromolar concentrations of LptD/EHis. 
Since an upper plateau could not be observed, a reliable Kd for this interaction could not be 
derived. 
 
A 
 
 
B      C 
 
 
Figure S7. A, FP assay of thanatin-BDP-FL and D-thanatin-BDP-FL binding to LptD/EHis in 
TBS buffer with 1% OG. B,C, Binding assays to LptD/EHis using a Monolith NT.115 
instrument (NanoTemper Technologies) recording both changes due to the thermophoresis 
effect (B), and total fluorescence changes (C), with both thanatin-Cy3 and D-thanatin-Cy3. 
Measurements were done in triplicate with standard deviation shown. 
 
 
 
11. NMR studies and structure determination of thanatin-LptAm complex 
 
Annotated [15N,1H]-HSQC spectra are shown in Figures S8 and S9 for LptAm or thanatin in 
free and complexed states. Note that numbering of LptA refers to the full-length sequence 
including the signalling sequence. Therefore, residue 28 in these annotations corresponds to 
the first residue of LptAm after removal of the signal sequence. 
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Figure S8. Assigned [15N,1H]-HSQC spectra of 15N-labeled LptAm in free form (top) and after 
addition of 1.2 equiv. of unlabeled thanatin (center). The bottom panel shows the overlay of 
both spectra. The complex is depicted with red contours. 
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Figure S9. [15N,1H]-HSQC spectra of 15N-labeled thanatin in free form (A) and after addition 
of 1.2 equiv. of unlabeled LptAm (B). The bottom panel shows the overlay of both spectra. 
The complex is depicted with red contours. In the PDB coordinates 6GD5 of the complex the 
first residue of thanatin has residue number 201 
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NMR Binding site studies  
Chemical shift perturbations between the free and thanatin-bound LptAm were calculated 
according to 
        
in which subscripts f and b denote free and complexed states (42) (Figure S10).  
 
Figure S10. Weighted 15N,1H chemical shift changes (∆δ) between the free and thanatin-
bound LptAm as a function of residue number. 
 
 
 
NOE analysis, structure calculations and refinement 
The solution structure of the LptAm:thanatin complex was determined using distance 
restraints derived from a set of NOESY spectra (vide supra) and torsion angle restraints 
derived from TALOS+. TALOS+ predicted 14 β-strands and a short N-terminal α-helix 
(Figure S11) but yielded no unambiguous predictions for the C-terminal segment (144-170) 
and the loop region connecting strands β6 and β7. Unassigned peak lists were annotated 
using the “noeassign” macro of CYANA 3.97 (43, 44), which in an iterative fashion matches 
peaks to known chemical shifts, and attempts to resolve ambiguous assignments based on 
preliminary structure calculations and network anchoring. To improve convergence of the 
calculations, the coordinates of the first noeassign cycle were initially replaced by a model 
complex based on the X-ray structure of E. coli LptA (pdb code 2R1A) (9) and the solution 
structure of thanatin (pdb code 8TFV) (45). Two different starting orientations (parallel and 
anti-parallel beta-sheet complementation) of thanatin were tested. When the model was not 
supplied after the first cycle the computed structure was similar, but the resolution was lower 
because some long-range NOEs were not correctly identified. Nevertheless, it was very 
clear that the beta strands of LptAm and thanatin complemented each other in a parallel 
fashion. Once the overall topology was clear, NOESY spectra were manually inspected and 
many more interfacial long-range NOEs identified. 
 In total, 1085 NOE upper distance restraints distributed through residues 29-139 of 
LptAm and residues 2-21 of thanatin were applied in the final structure calculations. During 
the simulated annealing procedure 202 dihedral angle restraints derived from TALOS were 
applied. The target-function of the 20-lowest energy conformers was about 1.7. Finally, the 
20 lowest CYANA conformers were refined in explicit water using the CHARMM22 
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parallhdg5.3 force-field as implemented in XPLOR-NIH (46). The scripts from the xplor-nih-
tutorial-2014/gb1_rdc distribution were utilized for refinement. Important parameters of the 
structure calculation, the refinement, and superposition RMSDs as well as figures for the 
quality of the obtained structures are presented in Table S7.  
 The final bundle of 20 low energy structures for LptAm-thanatin complex reveals good 
definition of the structured parts of LptAm (residues 30-143) and thanatin (residues 4-20) 
(Figure S11), characterized by a backbone RMSD of 0.8 ± 0.2 Å. 99.7% of the φ/ψ dihedral 
combinations are located in the most favoured regions of the Ramachandran plot and only 
0.4% in the disallowed regions. A summary of the structure calculation statistics is given in 
Table S8. The coordinates of the structured parts are deposited in the pdb database under 
accession code 6GD5. 
 
 
Figure S11. Ribbon representation of the 20 lowest-energy NMR conformers in two different 
orientations. Backbone atoms of residues 30-143 were superimposed. The flexible C-
terminus of LptA encompassing residues 144-170 is not shown. LptAm and thanatin are 
depicted in green and red, respectively. 
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Comparison of the jellyroll domains in LptA and LptD 
Based on a sequence and structure alignment of the N-terminal ß-strands in the β-jellyroll 
domain of LptD and the β-jellyroll of LptA it can be seen that residues of LptA involved in 
thanatin binding are identical or similar in LptD (Figure S12).  
 
 
Figure S12. (Top) Sequence alignment of LptA (res. 28-76) and LptD (res. 43-91).  
Residues in LptA interacting with thanatin in the complex (Figure S11) are marked with 
stars. (Bottom) Superimposition of LptD N-terminal domain (from the crystal structure PDB 
4Q35, res. 43-91, blue) with LptA (crystal structure PDB 2R1A, res. 28-76, chain C, violet) 
shown in the sequence alignment (Top). The side chains of residues which are situated in 
the thanatin binding site (Figure S11) are displayed in ball-and-stick representation. 
 
 
 
 
This close similarity between the N-terminal regions of LptA and LptD suggests that thanatin 
should bind to this region of LptD. 
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Table S7. Statistics from the NMR structure calculations for LptAm-thanatin.  
 
 
Input data for structure calculation 
 
 
NOE distance restraints  
total 1085 
Intra-residue, i-j=0 285 
Sequential, i-j=1 334 
Medium-range, 1<i-j<5 62 
Long-range, i-j ≥ 5 404 
Torsion angle constraints 202 
  
Structure statistics, 20 conformers  
CYANA target function value (Å2) 1.7 
 
Energies (kcal/mol)  
  
Total -4305 ± 168 
Distance restraints 32 ± 5 
  
Satisfaction of Experimental Constraints:  
  
NOE distance restraints  
  
Max Violations per structure                0.30 ± 0.02 
RMSD of violations 0.01 ± 0.00 
  
Torsion angle restraints  
Max Violations per structure 11.5 ± 1.40 
RMSD of violations 1.33 ± 0.15 
  
PROCHECK Ramachandran plot analysis  
  
Residues in favored regions (%) 76.9 
Residues in additional allowed regions (%) 22.9 
Residues in generously allowed regions (%) 0.1 
Residues in disallowed regions (%) 0.2 
  
Root mean square deviation to the average 
coordinates (Å) 
 
  
Backbone atoms (residues 30-143,4-20) 1.33 ± 0.32 
Backbone atoms (regular secondary structure)a 0.85 ± 0.22 
Heavy atoms  (residues 30-143, 4-20) 1.85 ± 0.31 
Heavy atoms (regular secondary structure)a 1.31 ± 0.20 
a residues 31-45, 51-75, 85-97, 106-115,123-130,135-141 and thanatin 4-20 
 
 
 
 
 
